LICENSE AGREEMENTLicense Agreement • March 17th, 2014 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research
This License Agreement (the “Agreement”) is entered into this 20th day of September 2013 (the “Effective Date”) by and between Phyxius Pharma Inc., a company incorporated under the laws of State of Delaware (“Licensee”) and Orion Corporation, a company incorporated under the laws of Finland (“Orion”). Licensee and Orion may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
AMENDMENT TO COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • March 17th, 2014 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research
THIS AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of January 31, 2014, by and between Oxygen Biotherapeutics, Inc., a Delaware corporation (the “Company”) and JP SPC 3 obo OXBT FUND, SP (the “Holder”) amends that certain Common Stock Purchase Warrant issued by the Company to the Holder with respect to 2,358,975 shares of the Company’s Common Stock and with an Initial Exercise Date of August 22, 2013 (the “Warrant”). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Warrant.
